港股異動 | 先聲藥業(2096.HK)續漲4.57% 與淩科藥業合作 引進選擇性JAK1抑制劑
格隆匯3月21日丨先聲藥業(2096.HK)續漲4.57%,報10.3港元,總市值271億港元。該公司3月18日午後公佈,與淩科藥業於今日簽署合作協議,根據協議條款,集團將獲得LNK01001在中國境內針對類風濕關節炎和強直性脊柱炎適應症的獨家商業化權益並負責上市後推廣,淩科藥業將負責LNK01001的臨牀開發。根據現有的臨牀前及臨牀數據,與已上市JAK抑制劑相比,LNK01001具有更高選擇性和潛在更佳安全性,有望為患者提供更加安全有效的治療選擇。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.